
About Us
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

Leadership

Josh Riggs
President & Chief Executive Officer
Josh joined Oncocyte Corporation in August 2020 and was appointed Interim Chief Executive Officer in December 2022, after serving as Senior Director Business Development and General Manager, Transplant.

Prof. Dr. Ekkehard Schütz, MD, PhD, FAACC
Chief Science Officer
Ekkehard (Ekke) joined Oncocyte in April 2021 through the acquisition of Chronix Biomedical. Ekke serves as the managing director of Chronix Biomedical GmbH, wholly owned by Oncocyte and CMO for Europe. As an adjunct professor, he teaches molecular genetics and diagnostics at the Georg-August-University.

Yuh-Min (Johnson) Chiang, PhD
Chief Technology Officer
Johnson joined Oncocyte Corporate in September 2021. Prior to joining Oncocyte, Johnson holds the Chief Technology Officer in Alveo Technologies, an IVD company focusing on development of cutting edge molecular diagnostic tests for Over The Counter (OTC) and Point-Of-Care (POC) applications. Johnson led the teams to develop the COVID-19 be.well Test for a successful US clinical trial and obtained the CE mark and UK approval.

Andrea James
Chief Financial Officer
Prior to joining Oncocyte, Andrea served as chief communications officer and head of investor relations at Axon Enterprise, Inc. (Nasdaq: AXON). She joined Axon’s finance team in 2017 to build the company’s investor relations function and played an integral role through the company’s growth from $1 billion in market capitalization to a company valued at more than $20 billion. She led Axon’s repositioning as a top-tier technology company with the investment community and established Axon’s corporate strategy function, overseeing capital stewardship, mergers and acquisitions, strategic partnerships and investments. Her work was instrumental in supporting more than $550 million in equity capital offerings.

Sandra O’Donald
Senior Vice President, Business Operations
Sandra joined Oncocyte Corporation in December 2019 and was appointed SVP, Business Operations, after serving as VP, Operations & PMO, and Director of PMO.
She brings over 20 years of experience by combining a business management background with strategy, operations, P&L, commercialization, and integration experience.

Ryan Andrews
Vice President, Commercial
Ryan joined Oncocyte Corporation in August 2019 and was appointed VP, Commercial after serving as Sr. Director, Marketing and Director of Marketing. Prior to joining Oncocyte, Ryan was principal at Bethesda Group, LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.

Peter Hong
Vice President, General Counsel
Peter joined Oncocyte in August 2021 as Vice President, General Counsel. Prior to joining Oncocyte, Peter was an associate at Stradling Yocca Carlson & Rauth, P.C. where he represented public and private companies in capital markets, M&A and corporate governance matters. Before joining Stradling, Peter was an associate at the New York office of Covington & Burling LLP where he represented underwriters in the initial public offerings and follow-on offerings of biotechnology companies.

James Liu
Vice President of Accounting, Controller, Treasurer, and Principal Accounting Officer
James joined Oncocyte Corporation in July 2021 and was appointed Vice President of Accounting, Controller, Treasurer, and Principal Accounting Officer in March 2025. He has held several key roles at Oncocyte, including Senior Director, Controller & Principal Accounting Officer and Manager of SEC Reporting & Compliance. James also served as interim Principal Financial Officer from August 2023 to June 2024, overseeing financial operations and public company reporting.
